JPRN-jRCT1030210361招募中未知
Additional TR study on Phase 2 study of Trastuzumab Deruxtecan in the neoadjuvant treatment for patients with HER2 positive gastric and gastroesophageal junction adenocarcinoma - T-DXd_NAC TR
Shitara Kohei0 个研究点目标入组 37 人开始时间: 2021年10月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients enrolled in the Phase 2 study of Trastuzumab Deruxtecan in the neoadjuvant treatment for patients with HER2 positive gastric and gastroesophageal junction adenocarcinoma who have consented for the study will be included.
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Phase II study of Trastuzuman in combination with TS-1 and Cisplatin for patients with Human Epidermal Growth Facter Receptor type-2 (HER-2)-positive Advanced Gastric CancerGastric cancerJPRN-UMIN000008389West Japan Oncology Group55
招募中
2 期
Phase II, multicenter, open-label study of Trastuzumab derxtecan in patients with HER2-expressing recurrent and or metastatic salivary gland carcinomaHER2-expressing recurrent and/or metastatic salivary gland carcinomaHER2-expressing, salivary gland carcinoma, recurrent and/or metastaticJPRN-jRCT2011210017Hirotoshi Akita52
招募中
不适用
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancerNeoplasmsKCT0004391Asan Medical Center28
进行中（未招募）
1 期
A phase 2 clinical trial conducted investigate the effectiveness of trastuzumab deruxtecan (T-DXd) administered before surgery for the treatment of HER-2 positive breast cancer.HER2-positive breast cancer.MedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-002485-32-IECancer Trials Ireland80
已完成
不适用
Prospective study of TS-1 / CPT-11 plus Trastuzumab in patients with HER-2 positive metastatic breast cancer (KSCOG-BC02)Breast CancerJPRN-UMIN000008647Kurume University School of Medicine30